Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC-Early Clinical Studies Group (ECSG)

Annals of Oncology

Volumn 12, Issue 9, 2001, Pages 1289-1293

  Punt, C J A ^a   Fumoleau, P ^b   Van De Walle, B ^a   Faber, M N ^c   Ravic, M ^d   Campone, M ^d  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Institut de Cancerologie de l'Ouest   (France)

^c NDDO Oncology   (Netherlands)

^d NONE

Author keywords

Cancer; Chemotherapy; E7070; Pharmacokinetics; Phase I; Sulphonamide

Indexed keywords

ANTIEMETIC AGENT; BENZENESULFONAMIDE DERIVATIVE; INDISULAM; SULFONAMIDE; UNCLASSIFIED DRUG; [N [3 CHLORO 7 INDOYL] 1,4 BENZENESULFONAMIDE];

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER THERAPY; CELL CYCLE G1 PHASE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG MECHANISM; DRUG TOXICITY; FEBRILE NEUTROPENIA; FEMALE; FOLLICULITIS; HUMAN; MALE; MAXIMUM TOLERATED DOSE; MEDICAL DOCUMENTATION; NONLINEAR SYSTEM; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOLID TUMOR; STANDARD; STOMATITIS; THROMBOCYTOPENIA;

EID: 0034772246     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012287111922     Document Type: Article

References (5)

1. Discovery of novel antitumor sulfonamides targeting G1 phase of the cell cycle
2. Phase I and pharmacokinetic study of E7070, a novel sulphonamide, given daily × 5 every three weeks as a one-hour infusion in patients with advanced solid tumors
3. Phase I and pharmacokinetic study of E7070, a new chloro-indolylsulfonamide, given as a one-hour infusion every three weeks in patients with advanced solid tumors
4. Phase I and pharmacokinetic study of E7070 in patients with solid tumors as single IV infusion, weekly × 4, Q six weeks
5. Phase I trial of five-days continuous infusion E7070 [N(3-chloro 7 indolyl)-1,4 benzene-disulfonamide] in patients with solid tumors